Kimberly-Clark (KMB) 10-Q 25 Oct 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Oct. 18, 2021
Entity Information [Line Items]
Document Type		10-Q
Document Period End Date		Sep. 30, 2021
Entity File Number		1-225
Entity Registrant Name		KIMBERLY-CLARK CORPORATON
Entity Incorporation, State or Country Code		DE
Entity Tax Identification Number		39-0394230
Entity Address, Address Line One		P.O. Box 619100
Entity Address, City or Town		Dallas,
Entity Address, State or Province		TX
Entity Address, Postal Zip Code	75261-9100
City Area Code	972
Local Phone Number	281-1200
Entity Current Reporting Status		Yes
Entity Interactive Data Current		Yes
Entity Filer Category		Large Accelerated Filer
Entity Small Business		false
Entity Emerging Growth Company		false
Entity Common Stock, Shares Outstanding			336,716,722
Document Quarterly Report		true
Document Transition Report		false
Entity Shell Company		false
Document Fiscal Year Focus		2021
Document Fiscal Period Focus		Q3
Entity Central Index Key		0000055785
Current Fiscal Year End Date		--12-31
Amendment Flag		false
Common Stock | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security		Common Stock
Trading Symbol		KMB
Security Exchange Name		NYSE
0.625% Notes Due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security		0.625% Notes due 2024
Trading Symbol		KMB24
Security Exchange Name		NYSE

Consolidated Income Statement

Consolidated Income Statement - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net Sales	$ 5,010	$ 4,683	$ 14,475	$ 14,304
Cost of products sold	3,527	3,093	9,923	9,146
Gross Profit	1,483	1,590	4,552	5,158
Marketing, research and general expenses	819	919	2,488	2,636
Other (income) and expense, net	7	5	24	27
Operating Profit	657	666	2,040	2,495
Nonoperating expense	(10)	(40)	(71)	(57)
Interest income	1	2	4	6
Interest expense	(64)	(62)	(192)	(188)
Income Before Income Taxes and Equity Interests	584	566	1,781	2,256
Provision for income taxes	(126)	(114)	(386)	(510)
Income Before Equity Interests	458	452	1,395	1,746
Share of net income of equity companies	21	31	88	104
Net income	479	483	1,483	1,850
Net income attributable to noncontrolling interests	(10)	(11)	(26)	(37)
Net Income Attributable to Kimberly-Clark Corporation	$ 469	$ 472	$ 1,457	$ 1,813
Per Share Basis
Basic	$ 1.39	$ 1.38	$ 4.32	$ 5.32
Diluted	$ 1.39	$ 1.38	$ 4.31	$ 5.30

Consolidated Statement Of Compr

Consolidated Statement Of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net Income	$ 479	$ 483	$ 1,483	$ 1,850
Other Comprehensive Income (Loss), Net of Tax
Unrealized currency translation adjustments	(151)	38	(288)	(236)
Employee postretirement benefits	16	0	45	39
Other	35	(3)	93	5
Total Other Comprehensive Income (Loss), Net of Tax	(100)	35	(150)	(192)
Comprehensive Income	379	518	1,333	1,658
Comprehensive income attributable to noncontrolling interests	1	(16)	(8)	(34)
Comprehensive Income Attributable to Kimberly-Clark Corporation	$ 380	$ 502	$ 1,325	$ 1,624

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($) shares in Millions, $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 286	$ 303
Accounts receivable, net	2,399	2,235
Inventories	2,098	1,903
Other current assets	843	733
Total Current Assets	5,626	5,174
Property, Plant and Equipment, Net	7,964	8,042
Investments in Equity Companies	340	300
Goodwill	1,796	1,895
Other Intangible Assets, Net	810	832
Other Assets	1,239	1,280
TOTAL ASSETS	17,775	17,523
Current Liabilities
Debt payable within one year	1,387	486
Trade accounts payable	3,519	3,336
Accrued expenses and other current liabilities	1,972	2,262
Dividends payable	380	359
Total Current Liabilities	7,258	6,443
Long-Term Debt	7,555	7,878
Noncurrent Employee Benefits	869	864
Deferred Income Taxes	701	723
Other Liabilities	657	718
Redeemable Preferred Securities of Subsidiaries	$ 28	$ 28
Preferred Stock, Shares Issued	0
Preferred Stock, Shares Authorized	20	20
Preferred Stock, Par or Stated Value Per Share	$ 0	$ 0
Common Stock, Shares, Issued	378.6	378.6
Common Stock, Shares Authorized	1,200	1,200
Common Stock, Par or Stated Value Per Share	$ 1.25	$ 1.25
Stockholders' Equity
Preferred Stock, Value, Issued	$ 0	$ 0
Common Stock, Value, Issued	473	473
Additional Paid in Capital	$ 614	$ 657
Treasury Stock, Shares	41.9	39.9
Treasury Stock, Value	$ (5,191)	$ (4,899)
Retained Earnings (Accumulated Deficit)	7,883	7,567
Accumulated Other Comprehensive Income (loss)	(3,305)	(3,172)
Total Kimberly-Clark Corporation Stockholders' Equity	474	626
Noncontrolling Interests	233	243
Total Stockholders' Equity	707	869
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 17,775	$ 17,523

Consolidated Balance Sheet Pare

Consolidated Balance Sheet Parenthetical - $ / shares shares in Millions	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred Stock, Par or Stated Value Per Share	$ 0	$ 0
Preferred Stock, Shares Authorized	20	20
Preferred Stock, Shares Issued	0
Common Stock, Par or Stated Value Per Share	$ 1.25	$ 1.25
Common Stock, Shares Authorized	1,200	1,200
Common Stock, Shares, Issued	378.6	378.6
Treasury Stock, Shares	41.9	39.9

Statement of Stockholders' Equi

Statement of Stockholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	AOCI Attributable to Parent	Noncontrolling Interests
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued		$ 473
Additional Paid in Capital			$ 556
Treasury Stock, Shares				37,149
Treasury Stock, Value				$ (4,454)
Retained Earnings					$ 6,686
Accumulated Other Comprehensive Income (Loss)						$ 3,294
Noncontrolling Interests							$ 227
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 194
Net income	1,850				1,813
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest							34
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excludes Redeemable Interests' Share	1,847
Other Comprehensive Income, Net of Tax	192					189	(2)
Other Comprehensive Income (Loss), Net of Tax, Excludes Redeemable Interests' Share	(191)
Stock-based awards exercised or vested	212		(54)	$ 266
Treasury Stock, Shares, Acquired				3,327
Treasury Stock, Value, Acquired, Cost Method				$ (473)
Recognition of stock-based compensation	98		98
Dividends, Common Stock, Cash	(1,112)				(1,095)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders							(17)
Other	$ (2)		10		(9)	(1)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures				(2,294)
Dividends declared	$ 3.21
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued		$ 473
Additional Paid in Capital			554
Treasury Stock, Shares				37,574
Treasury Stock, Value				$ (4,545)
Retained Earnings					7,299
Accumulated Other Comprehensive Income (Loss)						3,513
Noncontrolling Interests							227
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 495
Net income	483				472
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest							10
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excludes Redeemable Interests' Share	482
Other Comprehensive Income, Net of Tax	(35)					(30)	6
Other Comprehensive Income (Loss), Net of Tax, Excludes Redeemable Interests' Share	36
Stock-based awards exercised or vested	77		(2)	$ 79
Treasury Stock, Shares, Acquired				1,280
Treasury Stock, Value, Acquired, Cost Method				$ (195)
Recognition of stock-based compensation	45		45
Dividends, Common Stock, Cash	(365)				(365)
Other	$ (2)		13		(11)	(1)	(1)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures				(672)
Dividends declared	$ 1.07
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued		$ 473
Additional Paid in Capital			610
Treasury Stock, Shares				38,182
Treasury Stock, Value				$ (4,661)
Retained Earnings					7,395
Accumulated Other Comprehensive Income (Loss)						3,482
Noncontrolling Interests							242
Total Kimberly-Clark Corporation Stockholders' Equity	$ 577
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued	473	$ 473
Additional Paid in Capital	$ 657		657
Treasury Stock, Shares	39,900			39,873
Treasury Stock, Value	$ (4,899)			$ (4,899)
Retained Earnings	7,567				7,567
Accumulated Other Comprehensive Income (Loss)	3,172					3,172
Noncontrolling Interests	243						243
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	869
Total Kimberly-Clark Corporation Stockholders' Equity	626
Net income	1,483				1,457
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest							25
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excludes Redeemable Interests' Share	1,482
Other Comprehensive Income, Net of Tax	150					132	(18)
Other Comprehensive Income (Loss), Net of Tax, Excludes Redeemable Interests' Share	(150)
Stock-based awards exercised or vested	52		(78)	$ 130
Treasury Stock, Shares, Acquired				3,169
Treasury Stock, Value, Acquired, Cost Method				$ (422)
Recognition of stock-based compensation	28		28
Dividends, Common Stock, Cash	(1,171)				(1,154)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders							(17)
Other	$ (19)		7		13	1
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures				(1,189)
Dividends declared	$ 3.42
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued		$ 473
Additional Paid in Capital			627
Treasury Stock, Shares				41,661
Treasury Stock, Value				$ (5,159)
Retained Earnings					7,798
Accumulated Other Comprehensive Income (Loss)						3,215
Noncontrolling Interests							234
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 758
Net income	479				469
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest							10
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excludes Redeemable Interests' Share	479
Other Comprehensive Income, Net of Tax	100					89	(11)
Other Comprehensive Income (Loss), Net of Tax, Excludes Redeemable Interests' Share	(100)
Stock-based awards exercised or vested	25		(1)	$ 26
Treasury Stock, Shares, Acquired				429
Treasury Stock, Value, Acquired, Cost Method				$ (58)
Recognition of stock-based compensation	(13)		(13)
Dividends, Common Stock, Cash	$ (384)				(384)
Other			1			1
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures				(237)
Dividends declared	$ 1.14
Common Stock, Shares, Issued		378,597
Common Stock, Value, Issued	$ 473	$ 473
Additional Paid in Capital	$ 614		$ 614
Treasury Stock, Shares	41,900			41,853
Treasury Stock, Value	$ (5,191)			$ (5,191)
Retained Earnings	7,883				$ 7,883
Accumulated Other Comprehensive Income (Loss)	3,305					$ 3,305
Noncontrolling Interests	233						$ 233
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	707
Total Kimberly-Clark Corporation Stockholders' Equity	$ 474

Statement of Stockholders' Eq_2

Statement of Stockholders' Equity Stockholders' Equity Parentheticals - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]
Dividends declared	$ 1.14	$ 1.07	$ 3.42	$ 3.21

Consolidated Cash Flow Statemen

Consolidated Cash Flow Statement - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating Activities
Net income	$ 1,483	$ 1,850
Depreciation and amortization	572	606
Asset impairments	3	0
Stock-based compensation	30	101
Deferred income taxes	(42)	(30)
Net (gains) losses on asset dispositions	34	67
Equity companies' earnings (in excess of) less than dividends paid	(25)	(53)
Operating working capital	(432)	292
Postretirement benefits	39	7
Other	6	2
Cash Provided by Operations	1,668	2,842
Investing Activities
Capital spending	(734)	(894)
Proceeds from dispositions of property	31	5
Investments in time deposits	(632)	(509)
Maturities of time deposits	598	404
Other	1	17
Cash Used for Investing	(736)	(977)
Financing Activities
Cash dividends paid	(1,133)	(1,087)
Change in short-term debt	854	(497)
Debt proceeds	5	1,842
Debt repayments	(269)	(753)
Proceeds from exercise of stock options	52	212
Acquisitions of common stock for the treasury	(393)	(449)
Other	(57)	(40)
Cash Used for Financing	(941)	(772)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(8)	(17)
Change in Cash and Cash Equivalents	(17)	1,076
Cash and Cash Equivalents - Beginning of Period	303	442
Cash and Cash Equivalents - End of Period	$ 286	$ 1,518

Accounting Policies

Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Accounting Policies	Accounting Policies Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted. For further information, refer to the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries. Highly Inflationary Accounting in Argentina GAAP guidance requires the use of highly inflationary accounting for countries whose cumulative three-year inflation exceeds 100 percent. In the second quarter of 2018, published inflation indices indicated that the three-year cumulative inflation in Argentina exceeded 100 percent, and as of July 1, 2018, we elected to adopt highly inflationary accounting for our subsidiaries in Argentina (“K-C Argentina”). Under highly inflationary accounting, K-C Argentina’s functional currency became the U.S. dollar, and its income statement and balance sheet have been measured in U.S. dollars using both current and historical rates of exchange. The effect of changes in exchange rates on peso-denominated monetary assets and liabilities has been reflected in earnings in Other (income) and expense, net and was not material. As of September 30, 2021, K-C Argentina had a small net peso monetary position. Net sales of K-C Argentina were approximately 1 percent of our consolidated net sales for the nine months ended September 30, 2021 and 2020. Recently Adopted Accounting Standard In 2019, the Financial Accounting Standards Board issued Accounting Standards Update No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) . The new guidance simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the tax basis of goodwill after a business combination, and the recognition of deferred tax liabilities for outside basis differences. The new guidance also changes the calculation of the income tax impact of hybrid taxes and the methodology for calculating income taxes in an interim period. We adopted this standard as of January 1, 2021 on either a prospective basis or through a modified retrospective approach, as required by the standard. There was no cumulative effect adjustment recorded to retained earnings as the amount was not material. The effects of this standard on our financial position, results of operations and cash flows were not material.

2018 Global Restructuring Progr

2018 Global Restructuring Program	9 Months Ended
	Sep. 30, 2021
2018 Global Restructuring Program
Restructuring Cost and Reserve
Restructuring and Related Activities Disclosure	2018 Global Restructuring Program In January 2018, we announced the 2018 Global Restructuring Program to reduce our structural cost base by streamlining and simplifying our manufacturing supply chain and overhead organization. We expect to close or sell 11 manufacturing facilities and expand production capacity at several others. We expect to exit or divest some lower-margin businesses that generate approximately 1 percent of our net sales. The restructuring is expected to impact our organizations in all major geographies. Workforce reductions are expected to be in the range of 6,300 to 6,400. The restructuring is expected to be completed in 2021, with total costs now anticipated to be in the range of $2.1 billion to $2.2 billion pre-tax ($1.6 billion to $1.7 billion after tax). Cash costs are expected to be $1.15 billion to $1.2 billion, primarily related to workforce reductions. Non-cash charges are expected to be $950 to $1.0 billion pre-tax and will primarily consist of incremental depreciation, asset write-offs and pension settlement and curtailment charges. Restructuring charges in 2021 are now expected to be $280 to $380 pre-tax ($225 to $300 after tax). The following net charges were incurred in connection with the 2018 Global Restructuring Program: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cost of products sold: Charges (adjustments) for workforce reductions $ 5 $ 15 $ 3 $ 16 Asset impairments — — 3 — Asset write-offs 14 50 15 59 Incremental depreciation 2 18 10 86 Other exit costs 27 24 67 76 Total 48 107 98 237 Marketing, research and general expenses: Charges (adjustments) for workforce reductions 16 1 30 (1) Other exit costs 23 24 48 76 Total 39 25 78 75 Other (income) and expense, net 1 (1) 9 (1) Nonoperating expense 9 26 65 26 Total charges 97 157 250 337 Provision for income taxes (16) (50) (48) (83) Net charges 81 107 202 254 Net impact related to equity companies and noncontrolling interests (2) — (3) (1) Net charges attributable to Kimberly-Clark Corporation $ 79 $ 107 $ 199 $ 253 The following summarizes the restructuring liabilities activity: 2021 2020 Restructuring liabilities at January 1 $ 94 $ 132 Charges for workforce reductions and other cash exit costs 145 162 Cash payments (171) (177) Currency and other (3) (3) Restructuring liabilities at September 30 $ 65 $ 114 Restructuring liabilities of $48 and $80 are recorded in Accrued expenses and other current liabilities and $17 and $34 are recorded in Other Liabilities as of September 30, 2021 and 2020, respectively. The impact related to restructuring charges is recorded in Operating working capital and Other Operating Activities, as appropriate, in our consolidated cash flow statements.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Mergers, Acquisitions and Dispositions Disclosures	2020 Acquisition On October 1, 2020 (“Acquisition Date”), we acquired Softex Indonesia, in an all-cash transaction for approximately $1.2 billion. The transaction price, subject to working capital and net debt adjustments, resulted in a preliminary purchase price of $1.1 billion as of December 31, 2020 in addition to the assumption of certain indebtedness of Softex Indonesia at closing. The allocation of purchase consideration related to Softex Indonesia was substantially completed in the fourth quarter of 2020. We continue to evaluate potential contingencies that may have existed as of the acquisition date and expect to finalize the purchase price allocation no later than the fourth quarter of 2021. See Note 3, Acquisition, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 for the preliminary purchase price allocation, valuation methodology, and other information related to the Softex Indonesia acquisition.

Fair Value Information

Fair Value Information	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Information	Fair Value Information The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are: Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities. Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly. Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the nine months ended September 30, 2021 and for the full year 2020, there were no significant transfers to or from level 3 fair value determinations. Derivative assets and liabilities are measured on a recurring basis at fair value. At September 30, 2021 and December 31, 2020, derivative assets were $79 and $44, respectively, and derivative liabilities were $39 and $92, respectively. The fair values of derivatives used to manage interest rate risk and commodity price risk are based on LIBOR rates and interest rate swap curves and NYMEX price quotations, respectively. The fair values of hedging instruments used to manage foreign currency risk are based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. Measurement of our derivative assets and liabilities is considered a level 2 measurement. Additional information on our classification and use of derivative instruments is contained in Note 7. Redeemable preferred securities of subsidiaries are measured on a recurring basis at fair value and were $28 as of September 30, 2021 and December 31, 2020, respectively. They are not traded in active markets. The fair values of the redeemable securities were based on a discounted cash flow valuation model. Measurement of the redeemable preferred securities is considered a level 3 measurement. Company-owned life insurance ("COLI") assets are measured on a recurring basis at fair value. COLI assets were $73 at September 30, 2021 and December 31, 2020, respectively. The COLI policies are a source of funding primarily for our nonqualified employee benefits and are included in Other Assets. The COLI policies are measured at fair value using the net asset value per share practical expedient, and therefore, are not classified in the fair value hierarchy. The following table includes the fair value of our financial instruments for which disclosure of fair value is required: Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value September 30, 2021 December 31, 2020 Assets Cash and cash equivalents (a) 1 $ 286 $ 286 $ 303 $ 303 Time deposits (b) 1 368 368 364 364 Liabilities Short-term debt (c) 2 1,072 1,072 223 223 Long-term debt (d) 2 7,870 8,968 8,141 9,627 (a) Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value. (b) Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in Other current assets or Other Assets in the consolidated balance sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value. (c) Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value. (d) Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share ("EPS") There are no adjustments required to be made to net income for purposes of computing EPS. The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows: Three Months Ended Nine Months Ended (Millions of shares) 2021 2020 2021 2020 Basic 336.8 341.0 337.4 341.1 Dilutive effect of stock options and restricted share unit awards 0.7 1.3 1.0 1.2 Diluted 337.5 342.3 338.4 342.3 The impact of options outstanding that were not included in the computation of diluted EPS because their exercise price was greater than the average market price of the common shares was insignificant. The number of common shares outstanding as of September 30, 2021 and 2020 was 336.7 million and 340.4 million, respectively.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity Net unrealized currency gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries, except those in highly inflationary economies, are recorded in Accumulated Other Comprehensive Income ("AOCI"). For these operations, changes in exchange rates generally do not affect cash flows; therefore, unrealized translation adjustments are recorded in AOCI rather than net income. Upon sale or substantially complete liquidation of any of these subsidiaries, the applicable unrealized translation would be removed from AOCI and reported as part of the gain or loss on the sale or liquidation. Also included in unrealized translation amounts are the effects of foreign exchange rate changes on intercompany balances of a long-term investment nature and transactions designated as hedges of net foreign investments. The change in net unrealized currency translation for the nine months ended September 30, 2021 was primarily due to the weakening of foreign currencies versus the U.S. dollar, particularly the Korean won, the euro, the Australian dollar and the Peruvian sol. The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows: Unrealized Translation Defined Benefit Pension Plans Other Postretirement Benefit Plans Cash Flow Hedges and Other Balance as of December 31, 2019 $ (2,271) $ (979) $ (13) $ (31) Other comprehensive income (loss) before reclassifications (233) (19) 3 15 (Income) loss reclassified from AOCI — 57 (a) (1) (a) (10) Net current period other comprehensive income (loss) (233) 38 2 5 Balance as of September 30, 2020 $ (2,504) $ (941) $ (11) $ (26) Balance as of December 31, 2020 $ (2,157) $ (912) $ (40) $ (63) Other comprehensive income (loss) before (266) 5 (12) 56 (Income) loss reclassified from AOCI — 52 (a) (3) (a) 35 Net current period other comprehensive income (loss) (266) 57 (15) 91 Balance as of September 30, 2021 $ (2,423) $ (855) $ (55) $ 28 (a) Included in computation of net periodic benefit costs.

Objectives And Strategies For U

Objectives And Strategies For Using Derivatives	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Objectives And Strategies For Using Derivatives	Objectives and Strategies for Using DerivativesAs a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest rates, and commodity prices. We employ a number of practices to manage these risks, including operating and financing activities and, where appropriate, the use of derivative instruments. At September 30, 2021 and December 31, 2020, derivative assets were $79 and $44, respectively, and derivative liabilities were $39 and $92, respectively, primarily comprised of foreign currency exchange contracts. Derivative assets are recorded in Other current assets or Other Assets, as appropriate, and derivative liabilities are recorded in Accrued expenses and other current liabilities or Other Liabilities, as appropriate. Foreign Currency Exchange Rate Risk Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowings. A portion of our balance sheet translation exposure for certain affiliates, which results from changes in translation rates between the affiliates’ functional currencies and the U.S. dollar, is hedged with cross-currency swap contracts and certain foreign denominated debt which are designated as net investment hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged with primarily undesignated derivative instruments. Derivative instruments are entered into to hedge a portion of forecasted cash flows denominated in foreign currencies for non-U.S. operations' purchases of raw materials, which are priced in U.S. dollars, and imports of intercompany finished goods and work-in-process priced predominantly in U.S. dollars and euros. The derivative instruments used to manage these exposures are designated as cash flow hedges. Interest Rate Risk Interest rate risk is managed using a portfolio of variable and fixed-rate debt composed of short and long-term instruments. Interest rate swap contracts may be used to facilitate the maintenance of the desired ratio of variable and fixed-rate debt and are designated as fair value hedges. From time to time, we also hedge the anticipated issuance of fixed-rate debt, and these contracts are designated as cash flow hedges. Commodity Price Risk We use derivative instruments, such as forward contracts, to hedge a limited portion of our exposure to market risk arising from changes in prices of certain commodities. These derivatives are designated as cash flow hedges of specific quantities of the underlying commodity expected to be purchased in future months. In addition, we utilize negotiated short-term contract structures, including fixed price contracts, to manage volatility for a portion of our commodity costs. Fair Value Hedges Derivative instruments that are designated and qualify as fair value hedges are predominantly used to manage interest rate risk. The fair values of these interest rate derivative instruments are recorded as an asset or liability, as appropriate, with the offset recorded in Interest expense. The offset to the change in fair values of the related debt is also recorded in Interest expense. Any realized gain or loss on the derivatives that hedge interest rate risk is amortized to Interest expense over the life of the related debt. As of September 30, 2021, the aggregate notional values and carrying values of debt subject to outstanding interest rate contracts designated as fair value hedges were $625 and $638, respectively. For the nine months ended September 30, 2021 and 2020, gains or losses recognized in Interest expense for interest rate swaps were not significant. Cash Flow Hedges For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same income statement line and period that the hedged exposure affects earnings. As of September 30, 2021, outstanding commodity forward contracts were in place to hedge a limited portion of our estimated requirements of the related underlying commodities in the remainder of 2021 and future periods. As of September 30, 2021, the aggregate notional value of outstanding foreign exchange derivative contracts designated as cash flow hedges was $709. For the nine months ended September 30, 2021 and 2020, no significant gains or losses were reclassified into Interest expense, Cost of products sold or Other (income) and expense, net as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At September 30, 2021, amounts to be reclassified from AOCI into Interest expense, Cost of products sold or Other (income) and expense, net during the next twelve months are not expected to be material. The maximum maturity of cash flow hedges in place at September 30, 2021 is September 2023. Net Investment Hedges For derivative instruments that are designated and qualify as net investment hedges, the aggregate notional value was $1.5 billion at September 30, 2021. We exclude the interest accruals on cross-currency swap contracts and the forward points on foreign exchange forward contracts from the assessment and measurement of hedge effectiveness. We recognize the interest accruals on cross-currency swap contracts in earnings within Interest expense. We amortize the forward points on foreign exchange contracts into earnings within Interest expense over the life of the hedging relationship. Changes in fair value of net investment hedges are recorded in AOCI and offset the change in the value of the net investment being hedged. For the nine months ended September 30, 2021, unrealized gains of $69 related to net investment hedge fair value changes were recorded in AOCI and no significant amounts were reclassified from AOCI to Interest expense. No significant amounts were excluded from the assessment of net investment, fair value or cash flow hedge effectiveness as of September 30, 2021. Undesignated Hedging Instruments Gains or losses on undesignated foreign exchange hedging instruments are immediately recognized in Other (income) and expense, net. A loss of $2 and a gain of $23 were recorded in the three months ended September 30, 2021 and 2020, respectively. A loss of $8 and a gain of $31 were recorded in the nine months ended September 30, 2021 and 2020. The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. At September 30, 2021, the notional value of these undesignated derivative instruments was approximately $2.1 billion.

Description Of Business Segment

Description Of Business Segments	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information We are organized into operating segments based on product groupings. These operating segments have been aggregated into three reportable global business segments: Personal Care, Consumer Tissue and K-C Professional. The reportable segments were determined in accordance with how our chief operating decision maker and our executive managers develop and execute global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. Segment management is evaluated on several factors, including operating profit. Segment operating profit excludes Other (income) and expense, net and income and expense not associated with ongoing operations of the business segments, including the costs of corporate decisions related to the 2018 Global Restructuring Program described in Note 2. The principal sources of revenue in each global business segment are described below: • Personal Care brands offer our consumers a trusted partner in caring for themselves and their families by delivering confidence, protection and discretion through a wide variety of innovative solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products. Products in this segment are sold under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise and other brand names. • Consumer Tissue offers a wide variety of innovative solutions and trusted brands that responsibly improve everyday living for families around the world. Products in this segment include facial and bathroom tissue, paper towels, napkins and related products, and are sold under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve and other brand names. • K-C Professional partners with businesses to create Exceptional Workplaces, helping to make them healthier, safer and more productive through a range of solutions and supporting products such as wipers, tissue, towels, apparel, soaps and sanitizers. Our brands, including Kleenex, Scott, WypAll, Kimtech and KleenGuard are well known for quality and trusted to help people around the world work better. Information concerning consolidated operations by business segment is presented in the following tables: Three Months Ended September 30 Nine Months Ended September 30 2021 2020 Change 2021 2020 Change NET SALES Personal Care $ 2,656 $ 2,339 +14 % $ 7,635 $ 6,990 +9 % Consumer Tissue 1,541 1,623 -5 % 4,475 4,991 -10 % K-C Professional 797 705 +13 % 2,314 2,277 +2 % Corporate & Other 16 16 N.M. 51 46 N.M. TOTAL NET SALES $ 5,010 $ 4,683 +7 % $ 14,475 $ 14,304 +1 % OPERATING PROFIT Personal Care $ 496 $ 486 +2 % $ 1,431 $ 1,532 -7 % Consumer Tissue 222 318 -30 % 687 1,111 -38 % K-C Professional 96 87 +10 % 332 423 -22 % Corporate & Other (a) (150) (220) N.M. (386) (544) N.M. Other (income) and expense, net (a) 7 5 +40 % 24 27 -11 % TOTAL OPERATING PROFIT $ 657 $ 666 -1 % $ 2,040 $ 2,495 -18 % (a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including charges related to the 2018 Global Restructuring Program and Softex Indonesia acquisition-related costs. Restructuring charges related to the Personal Care, Consumer Tissue and K-C Professional business segments were $32, $42 and $10, respectively, for the three months ended September 30, 2021, $57, $59, and $15, respectively, for the three months ended September 30, 2020, $71, $84 and $19, respectively, for the nine months ended September 30, 2021, and $131, $135 and $41, respectively for the nine months ended September 30, 2020 . N.M. - Not Meaningful Sales of Principal Products: Three Months Ended September 30 Nine Months Ended September 30 (Billions of dollars) 2021 2020 2021 2020 Baby and child care products 1.8 1.6 5.3 4.8 Consumer tissue products 1.5 1.6 4.5 5.0 Away-from-home professional products 0.8 0.7 2.3 2.3 All other 0.9 0.8 2.4 2.2 Consolidated $ 5.0 $ 4.7 $ 14.5 $ 14.3

Supplemental Balance Sheet Data

Supplemental Balance Sheet Data	9 Months Ended
	Sep. 30, 2021
Statement of Financial Position [Abstract]
Additional Financial Information Disclosure	Supplemental Balance Sheet Data The following schedule presents a summary of inventories by major class: September 30, 2021 December 31, 2020 LIFO Non-LIFO Total LIFO Non-LIFO Total Raw materials $ 141 $ 342 $ 483 $ 131 $ 263 $ 394 Work in process 143 91 234 103 86 189 Finished goods 545 776 1,321 453 749 1,202 Supplies and other — 276 276 — 263 263 829 1,485 2,314 687 1,361 2,048 Excess of FIFO or weighted-average cost over (216) — (216) (145) — (145) Total $ 613 $ 1,485 $ 2,098 $ 542 $ 1,361 $ 1,903 Inventories are valued at the lower of cost or net realizable value, determined on the FIFO or weighted-average cost methods, and at the lower of cost or market, determined on the LIFO cost method. The following schedule presents a summary of property, plant and equipment, net: September 30, 2021 December 31, 2020 Land $ 169 $ 174 Buildings 2,959 2,932 Machinery and equipment 14,514 14,382 Construction in progress 700 845 18,342 18,333 Less accumulated depreciation (10,378) (10,291) Total $ 7,964 $ 8,042

2018 Global Restructuring Pro_2

2018 Global Restructuring Program (Tables) - 2018 Global Restructuring Program	9 Months Ended
	Sep. 30, 2021
Restructuring Cost and Reserve
Restructuring and Related Costs	The following net charges were incurred in connection with the 2018 Global Restructuring Program: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cost of products sold: Charges (adjustments) for workforce reductions $ 5 $ 15 $ 3 $ 16 Asset impairments — — 3 — Asset write-offs 14 50 15 59 Incremental depreciation 2 18 10 86 Other exit costs 27 24 67 76 Total 48 107 98 237 Marketing, research and general expenses: Charges (adjustments) for workforce reductions 16 1 30 (1) Other exit costs 23 24 48 76 Total 39 25 78 75 Other (income) and expense, net 1 (1) 9 (1) Nonoperating expense 9 26 65 26 Total charges 97 157 250 337 Provision for income taxes (16) (50) (48) (83) Net charges 81 107 202 254 Net impact related to equity companies and noncontrolling interests (2) — (3) (1) Net charges attributable to Kimberly-Clark Corporation $ 79 $ 107 $ 199 $ 253
Restructuring Reserve
Schedule of Restructuring Reserve by Type of Cost	The following summarizes the restructuring liabilities activity: 2021 2020 Restructuring liabilities at January 1 $ 94 $ 132 Charges for workforce reductions and other cash exit costs 145 162 Cash payments (171) (177) Currency and other (3) (3) Restructuring liabilities at September 30 $ 65 $ 114

Fair Value Information (Tables)

Fair Value Information (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair value of financial instruments	The following table includes the fair value of our financial instruments for which disclosure of fair value is required: Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value September 30, 2021 December 31, 2020 Assets Cash and cash equivalents (a) 1 $ 286 $ 286 $ 303 $ 303 Time deposits (b) 1 368 368 364 364 Liabilities Short-term debt (c) 2 1,072 1,072 223 223 Long-term debt (d) 2 7,870 8,968 8,141 9,627 (a) Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value. (b) Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in Other current assets or Other Assets in the consolidated balance sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value. (c) Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value. (d) Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Average Common Shares Outstanding Basic and Diluted	The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows: Three Months Ended Nine Months Ended (Millions of shares) 2021 2020 2021 2020 Basic 336.8 341.0 337.4 341.1 Dilutive effect of stock options and restricted share unit awards 0.7 1.3 1.0 1.2 Diluted 337.5 342.3 338.4 342.3

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss), Attributable to Kimberly-Clark Corporation	The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows: Unrealized Translation Defined Benefit Pension Plans Other Postretirement Benefit Plans Cash Flow Hedges and Other Balance as of December 31, 2019 $ (2,271) $ (979) $ (13) $ (31) Other comprehensive income (loss) before reclassifications (233) (19) 3 15 (Income) loss reclassified from AOCI — 57 (a) (1) (a) (10) Net current period other comprehensive income (loss) (233) 38 2 5 Balance as of September 30, 2020 $ (2,504) $ (941) $ (11) $ (26) Balance as of December 31, 2020 $ (2,157) $ (912) $ (40) $ (63) Other comprehensive income (loss) before (266) 5 (12) 56 (Income) loss reclassified from AOCI — 52 (a) (3) (a) 35 Net current period other comprehensive income (loss) (266) 57 (15) 91 Balance as of September 30, 2021 $ (2,423) $ (855) $ (55) $ 28 (a) Included in computation of net periodic benefit costs.

Description Of Business Segme_2

Description Of Business Segments (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from External Customer
Information Concerning Consolidated Operations by Business Segment	Information concerning consolidated operations by business segment is presented in the following tables: Three Months Ended September 30 Nine Months Ended September 30 2021 2020 Change 2021 2020 Change NET SALES Personal Care $ 2,656 $ 2,339 +14 % $ 7,635 $ 6,990 +9 % Consumer Tissue 1,541 1,623 -5 % 4,475 4,991 -10 % K-C Professional 797 705 +13 % 2,314 2,277 +2 % Corporate & Other 16 16 N.M. 51 46 N.M. TOTAL NET SALES $ 5,010 $ 4,683 +7 % $ 14,475 $ 14,304 +1 % OPERATING PROFIT Personal Care $ 496 $ 486 +2 % $ 1,431 $ 1,532 -7 % Consumer Tissue 222 318 -30 % 687 1,111 -38 % K-C Professional 96 87 +10 % 332 423 -22 % Corporate & Other (a) (150) (220) N.M. (386) (544) N.M. Other (income) and expense, net (a) 7 5 +40 % 24 27 -11 % TOTAL OPERATING PROFIT $ 657 $ 666 -1 % $ 2,040 $ 2,495 -18 % (a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including charges related to the 2018 Global Restructuring Program and Softex Indonesia acquisition-related costs. Restructuring charges related to the Personal Care, Consumer Tissue and K-C Professional business segments were $32, $42 and $10, respectively, for the three months ended September 30, 2021, $57, $59, and $15, respectively, for the three months ended September 30, 2020, $71, $84 and $19, respectively, for the nine months ended September 30, 2021, and $131, $135 and $41, respectively for the nine months ended September 30, 2020 . N.M. - Not Meaningful	[1]
Sales of Principal Products	Sales of Principal Products: Three Months Ended September 30 Nine Months Ended September 30 (Billions of dollars) 2021 2020 2021 2020 Baby and child care products 1.8 1.6 5.3 4.8 Consumer tissue products 1.5 1.6 4.5 5.0 Away-from-home professional products 0.8 0.7 2.3 2.3 All other 0.9 0.8 2.4 2.2 Consolidated $ 5.0 $ 4.7 $ 14.5 $ 14.3
[1]	Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including charges related to the 2018 Global Restructuring Program and Softex Indonesia acquisition-related costs. Restructuring charges related to the Personal Care, Consumer Tissue and K-C Professional business segments were $32, $42 and $10, respectively, for the three months ended September 30, 2021, $57, $59, and $15, respectively, for the three months ended September 30, 2020, $71, $84 and $19, respectively, for the nine months ended September 30, 2021, and $131, $135 and $41, respectively for the nine months ended September 30, 2020 . N.M. - Not Meaningful

Summary of Balance Sheet Data (

Summary of Balance Sheet Data (Tables)	9 Months Ended
	Sep. 30, 2021
Statement of Financial Position [Abstract]
Schedule of Inventory, Current	The following schedule presents a summary of inventories by major class: September 30, 2021 December 31, 2020 LIFO Non-LIFO Total LIFO Non-LIFO Total Raw materials $ 141 $ 342 $ 483 $ 131 $ 263 $ 394 Work in process 143 91 234 103 86 189 Finished goods 545 776 1,321 453 749 1,202 Supplies and other — 276 276 — 263 263 829 1,485 2,314 687 1,361 2,048 Excess of FIFO or weighted-average cost over (216) — (216) (145) — (145) Total $ 613 $ 1,485 $ 2,098 $ 542 $ 1,361 $ 1,903
Property, Plant and Equipment	The following schedule presents a summary of property, plant and equipment, net: September 30, 2021 December 31, 2020 Land $ 169 $ 174 Buildings 2,959 2,932 Machinery and equipment 14,514 14,382 Construction in progress 700 845 18,342 18,333 Less accumulated depreciation (10,378) (10,291) Total $ 7,964 $ 8,042

Accounting Policies Narrative (

Accounting Policies Narrative (Details)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Net sales | K-C Argentina | Geographic Concentration Risk
Accounting Policies
Net sales of K-C Argentina, percent	1.00%	1.00%

2018 Global Restructuring Pro_3

2018 Global Restructuring Program Narrative (Details) - 2018 Global Restructuring Program	3 Months Ended		9 Months Ended		45 Months Ended	48 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2021USD ($)Employee	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Restructuring Cost and Reserve
Restructuring Reserve	$ 65,000,000	$ 114,000,000	$ 65,000,000	$ 114,000,000	$ 65,000,000		$ 94,000,000	$ 132,000,000
Payments for Restructuring			(171,000,000)	(177,000,000)
Before Tax
Restructuring Cost and Reserve
Restructuring Charges	97,000,000	157,000,000	250,000,000	337,000,000	2,100,000,000
After Tax
Restructuring Cost and Reserve
Restructuring Charges	81,000,000	107,000,000	202,000,000	254,000,000	1,600,000,000
Accrued Expenses
Restructuring Cost and Reserve
Restructuring Reserve	48,000,000	80,000,000	48,000,000	80,000,000	48,000,000
Other current liabilities
Restructuring Cost and Reserve
Restructuring Reserve	$ 17,000,000	$ 34,000,000	$ 17,000,000	$ 34,000,000	$ 17,000,000
Minimum | Scenario, Forecast
Restructuring Cost and Reserve
Expected Number of Positions Eliminated | Employee						6,300
Minimum | Before Tax | Scenario, Forecast
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost						$ 2,100,000,000
Restructuring and Related Cost, Expected Cost Remaining						280,000,000
Minimum | After Tax | Scenario, Forecast
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost						1,600,000,000
Restructuring and Related Cost, Expected Cost Remaining						225,000,000
Minimum | Cash charges | Scenario, Forecast
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost						1,150,000,000
Minimum | Non-cash charges | Before Tax | Scenario, Forecast
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost						$ 950,000,000
Maximum | Scenario, Forecast
Restructuring Cost and Reserve
Expected Number of Positions Eliminated | Employee						6,400
Maximum | Before Tax | Scenario, Forecast
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost						$ 2,200,000,000
Restructuring and Related Cost, Expected Cost Remaining						380,000,000
Maximum | After Tax | Scenario, Forecast
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost						1,700,000,000
Restructuring and Related Cost, Expected Cost Remaining						300,000,000
Maximum | Cash charges | Scenario, Forecast
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost						1,200,000,000
Maximum | Non-cash charges | Before Tax | Scenario, Forecast
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost						$ 1,000,000,000

Restructuring and Related Activ

Restructuring and Related Activities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		45 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021
Restructuring Cost and Reserve
Asset impairments			$ 3	$ 0
Provision for income taxes	$ (126)	$ (114)	(386)	(510)
2018 Global Restructuring Program
Restructuring Cost and Reserve
Provision for income taxes	(16)	(50)	(48)	(83)
2018 Global Restructuring Program | Charges for workforce reductions
Restructuring Cost and Reserve
Restructuring Charges			(145)	(162)
2018 Global Restructuring Program | Before Tax
Restructuring Cost and Reserve
Restructuring Charges	(97)	(157)	(250)	(337)	$ (2,100)
2018 Global Restructuring Program | After Tax
Restructuring Cost and Reserve
Restructuring Charges	(81)	(107)	(202)	(254)	$ (1,600)
2018 Global Restructuring Program | After Tax | Equity Companies and Noncontrolling Interests
Restructuring Cost and Reserve
Restructuring Charges	2	0	3	1
2018 Global Restructuring Program | After Tax | Kimberly-Clark Corporation
Restructuring Cost and Reserve
Restructuring Charges	(79)	(107)	(199)	(253)
2018 Global Restructuring Program | Cost of Sales | Before Tax
Restructuring Cost and Reserve
Charges (adjustments) for workforce reductions	5	15	3	16
Asset impairments	0	0	3	0
Incremental depreciation	2	18	10	86
Other exit costs	27	24	67	76
Restructuring Charges	(48)	(107)	(98)	(237)
2018 Global Restructuring Program | Cost of Sales | Before Tax | Asset write-offs
Restructuring Cost and Reserve
Restructuring Charges	(14)	(50)	(15)	(59)
2018 Global Restructuring Program | Marketing, Research and General Expenses | Before Tax
Restructuring Cost and Reserve
Charges (adjustments) for workforce reductions	16	1	30	(1)
Other exit costs	23	24	48	76
Restructuring Charges	(39)	(25)	(78)	(75)
2018 Global Restructuring Program | Other Income | Before Tax
Restructuring Cost and Reserve
Restructuring Charges	$ (1)	$ 1	$ (9)	$ 1

2018 Global Restructuring Pro_4

2018 Global Restructuring Program Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		45 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021
Restructuring Cost and Reserve
Nonoperating expense	$ (10)	$ (40)	$ (71)	$ (57)
2018 Global Restructuring Program
Restructuring Cost and Reserve
Restructuring liabilities - January 1			94	132
Cash payments			(171)	(177)
Currency and other			(3)	(3)
2018 Global Restructuring Program | Before Tax
Restructuring Cost and Reserve
Charges for workforce reductions and other cash exit costs	97	157	250	337	$ 2,100
2018 Global Restructuring Program | Before Tax | Nonoperating expense
Restructuring Cost and Reserve
Nonoperating expense	$ 9	$ 26	65	26
2018 Global Restructuring Program | Workforce reductions and other exit costs
Restructuring Cost and Reserve
Charges for workforce reductions and other cash exit costs			$ 145	$ 162

Acquisition (Details)

Acquisition (Details) - USD ($) $ in Billions	Oct. 01, 2020	Sep. 30, 2021
Business Combinations [Abstract]
Payments to Acquire Businesses, Gross	$ 1.2	$ 1.1

Fair Value Information (Narrati

Fair Value Information (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Redeemable Preferred Securities Of Subsidiaries Fair Value Disclosure	$ 28	$ 28
Fair Value, Measurements, Recurring | Net Asset Value or Its Equivalent
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash Surrender Value, Fair Value Disclosure	73	73
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivatives Assets	79	44
Derivatives Liability	$ 39	$ 92

Fair Value Information (Fair Va

Fair Value Information (Fair Value Of Financial Instruments) (Details) - USD ($) $ in Millions		Sep. 30, 2021	Dec. 31, 2020
Carrying (Reported) Amount, Fair Value Disclosure | Fair Value, Inputs, Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash and cash equivalents	[1]	$ 286	$ 303
Time deposits	[2]	368	364
Carrying (Reported) Amount, Fair Value Disclosure | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Short-term debt	[3]	1,072	223
Long-term debt	[4]	7,870	8,141
Estimated Fair Value, Fair Value Disclosure | Fair Value, Inputs, Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash and cash equivalents	[1]	286	303
Time deposits	[2]	368	364
Estimated Fair Value, Fair Value Disclosure | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Short-term debt	[3]	1,072	223
Long-term debt	[4]	$ 8,968	$ 9,627
[1]	Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
[2]	Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in Other current assets or Other Assets in the consolidated balance sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
[3]	Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
[4]	Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares shares in Millions	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Common shares outstanding	336.7	340.4

Earnings Per Share (Average Com

Earnings Per Share (Average Common Shares Outstanding Basic And Diluted) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Average Common Shares Outstanding Basic and Diluted
Basic	336.8	341	337.4	341.1
Dilutive effect of stock options and restricted share unit awards	0.7	1.3	1	1.2
Diluted	337.5	342.3	338.4	342.3

Stockholders' Equity (Component

Stockholders' Equity (Components of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Net current period other comprehensive income (loss)		$ (151)	$ 38	$ (288)	$ (236)
Net current period other comprehensive income (loss)		16	0	45	39
Total Other Comprehensive Income (Loss), Net of Tax		(100)	35	(150)	(192)
Accumulated Other Comprehensive Income (loss)		(3,305)		(3,305)		$ (3,172)
Defined Benefit Pension Plans
Defined benefit and other postretirement benefit plans - Beginning balance				(912)	(979)
Other comprehensive income/(loss) before reclassifications				5	(19)
(Income)/loss reclassified from AOCI	[1]			52	57
Net current period other comprehensive income (loss)				57	38
Defined benefit and other postretirement benefit plans - Ending balance		(855)	(941)	(855)	(941)
Other Postretirement Benefit Plans
Defined benefit and other postretirement benefit plans - Beginning balance				(40)	(13)
Other comprehensive income/(loss) before reclassifications				(12)	3
(Income)/loss reclassified from AOCI	[1]			(3)	(1)
Net current period other comprehensive income (loss)				(15)	2
Defined benefit and other postretirement benefit plans - Ending balance		(55)	(11)	(55)	(11)
Unrealized Translation
Unrealized translation - Beginning balance				(2,157)	(2,271)
Other comprehensive income/(loss) before reclassifications				(266)	(233)
(Income)/loss reclassified from AOCI				0	0
Net current period other comprehensive income (loss)				(266)	(233)
Unrealized translation - Ending balance		(2,423)	(2,504)	(2,423)	(2,504)
Cash Flow Hedges and Other
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax				56	15
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax				35	(10)
Total Other Comprehensive Income (Loss), Net of Tax				91	5
Accumulated Other Comprehensive Income (loss)		$ 28	$ (26)	$ 28	$ (26)	$ (63)	$ (31)
[1]	Included in computation of net periodic benefit costs.

Objectives And Strategies For_2

Objectives And Strategies For Using Derivatives (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Derivative Instruments, Gain (Loss)
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax			$ 69
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss)
Gain (loss) on undesignated foreign exchange hedging instruments	$ 2	$ 23	(8)	$ 31
Foreign currency exchange contracts | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss)
Derivative, Notional Amount	2,100		2,100
Fair Value Hedging | Interest Rate Contract
Derivative Instruments, Gain (Loss)
Long-term Debt, Fair Value	638		638
Derivative, Notional Amount	625		625
Cash Flow Hedging | Foreign currency exchange contracts
Derivative Instruments, Gain (Loss)
Derivative, Notional Amount	709		709
Net Investment Hedging
Derivative Instruments, Gain (Loss)
Derivative, Notional Amount	1,500		1,500
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Derivative Instruments, Gain (Loss)
Derivative Asset	79		79		$ 44
Derivative Liability	$ 39		$ 39		$ 92

Description Of Business Segme_3

Description Of Business Segments (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended		45 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021
Net Sales		$ 5,010	$ 4,683	$ 14,475	$ 14,304
Sales Revenue, Net, Percent Change		7.00%		1.00%
Operating Profit		$ 657	666	$ 2,040	2,495
Other (income) and expense, net		$ 7	5	$ 24	27
Operating Profit, Percent Change		(1.00%)		(18.00%)
2018 Global Restructuring Program | Before Tax
Restructuring Charges		$ 97	157	$ 250	337	$ 2,100
Personal Care
Net Sales		$ 2,656	2,339	$ 7,635	6,990
Sales Revenue, Net, Percent Change		14.00%		9.00%
Operating Profit		$ 496	486	$ 1,431	1,532
Operating Profit, Percent Change		2.00%		(7.00%)
Personal Care | 2018 Global Restructuring Program | Before Tax
Restructuring Charges		$ 32	57	$ 71	131
Consumer Tissue
Net Sales		$ 1,541	1,623	$ 4,475	4,991
Sales Revenue, Net, Percent Change		(5.00%)		(10.00%)
Operating Profit		$ 222	318	$ 687	1,111
Operating Profit, Percent Change		(30.00%)		(38.00%)
Consumer Tissue | 2018 Global Restructuring Program | Before Tax
Restructuring Charges		$ 42	59	$ 84	135
K-C Professional
Net Sales		$ 797	705	$ 2,314	2,277
Sales Revenue, Net, Percent Change		13.00%		2.00%
Operating Profit		$ 96	87	$ 332	423
Operating Profit, Percent Change		10.00%		(22.00%)
K-C Professional | 2018 Global Restructuring Program | Before Tax
Restructuring Charges		$ 10	15	$ 19	41
Corporate and Other
Net Sales		16	16	51	46
Operating Profit	[1]	(150)	(220)	(386)	(544)
Other (income) and expense, net
Other (income) and expense, net	[1]	$ 7	$ 5	$ 24	$ 27
Operating Profit, Percent Change		40.00%		(11.00%)
[1]	Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including charges related to the 2018 Global Restructuring Program and Softex Indonesia acquisition-related costs. Restructuring charges related to the Personal Care, Consumer Tissue and K-C Professional business segments were $32, $42 and $10, respectively, for the three months ended September 30, 2021, $57, $59, and $15, respectively, for the three months ended September 30, 2020, $71, $84 and $19, respectively, for the nine months ended September 30, 2021, and $131, $135 and $41, respectively for the nine months ended September 30, 2020 . N.M. - Not Meaningful

Description Of Business Segme_4

Description Of Business Segments Sales of Principle Products (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Consolidated
Net Sales	$ 5,010	$ 4,683	$ 14,475	$ 14,304
Consumer Tissue Products
Consolidated
Net Sales	1,500	1,600	4,500	5,000
Baby and Child Care Products
Consolidated
Net Sales	1,800	1,600	5,300	4,800
Away-from-home Professional Products
Consolidated
Net Sales	800	700	2,300	2,300
All Other
Consolidated
Net Sales	$ 900	$ 800	$ 2,400	$ 2,200

Supplemental Balance Sheet Da_2

Supplemental Balance Sheet Data - Inventory (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Raw materials	$ 483	$ 394
Work in process	234	189
Finished goods	1,321	1,202
Supplies and other	276	263
Inventory, Gross	2,314	2,048
Inventory, LIFO Reserve	(216)	(145)
Total	2,098	1,903
LIFO
Raw materials	141	131
Work in process	143	103
Finished goods	545	453
Supplies and other	0	0
Inventory, Gross	829	687
Inventory, LIFO Reserve	(216)	(145)
Total	613	542
Non-LIFO
Raw materials	342	263
Work in process	91	86
Finished goods	776	749
Supplies and other	276	263
Inventory, Gross	1,485	1,361
Inventory, LIFO Reserve	0	0
Total	$ 1,485	$ 1,361

Supplemental Balance Sheet Da_3

Supplemental Balance Sheet Data - Property Plant and Equipment (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment
Land	$ 169	$ 174
Buildings	2,959	2,932
Machinery and equipment	14,514	14,382
Construction in progress	700	845
Property, Plant and Equipment, Gross	18,342	18,333
Less accumulated depreciation	(10,378)	(10,291)
Total	$ 7,964	$ 8,042